Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | MITF | O75030 | 2/20 | 0.74 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | HRH2 | P25021 | 1/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.74 |
| ▸ | HTR2B | P41595 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18782402 | 0.93 | MITF (0.85) | HTTMITFCHRM5ADRA2AADRA2C | |
| SCHEMBL2355493 | 0.93 | MITF (0.85) | HTTMITFCHRM5ADRA2AADRA2C | |
| SCHEMBL17348173 | 0.93 | HTT (0.74) | HTTMITFCHRM5ADRA2AADRA2C | |
| SCHEMBL17348135 | 0.92 | HTT (0.74) | HTTMITFCHRM5ADRA2AADRA2C | |
| SCHEMBL17338687 | 0.92 | HTT (0.74) | HTTMITFCHRM5ADRA2AADRA2C | |
| SCHEMBL17348152 | 0.91 | HTT (0.76) | HTTMITFCHRM5ADRA2AADRA2C | |
| SCHEMBL17348168 | 0.90 | CHRM5 (0.75) | HTTMITFCHRM5ADRA2AADRA2C | |
| SCHEMBL18782232 | 0.90 | CHRM5 (0.76) | HTTMITFCHRM5ADRA2AADRA2C | |
| SCHEMBL20979261 | 0.89 | HTT (0.74) | HTTMITFL3MBTL1MAPK1TP53 | |
| SCHEMBL17348141 | 0.89 | HTT (0.82) | HTTMITFCHRM5ADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154966-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | US HEALTH (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10202367-B2 | Heterocyclic compounds and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170114053-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2015192077-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202367-B2 | Heterocyclic compounds and methods of use thereof | HAVCR2, AR, AKR7A2 | HTT 2362/4885MITF 2310/4885CHRM5 3226/4885 |
| US-20170114053-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | HAVCR2, AR, AKR7A2 | HTT 2362/4885MITF 2310/4885CHRM5 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.